The patient monitoring company is also facing a slowdown in demand for the consumer audio products it acquired in a deal last year.
Masimo lowers outlook, citing constrained hospital budgets Read More »
Many payers beat Wall Street expectations in the quarter, despite ongoing utilization concerns. Other hot topics? Medicare Advantage stars, Medicaid redeterminations, individual exchange growth and GLP-1s.
Biggest takeaways from health insurers’ third-quarter earnings Read More »
The company’s diagnostics unit continued to struggle amid layoffs and reports of a potential sale.
Siemens Healthineers’ Varian rebounds; execs mum on diagnostics sale rumors Read More »
Obesity drugs are constraining Intuitive’s growth today, but the robotic surgery specialist could receive a sales boost in 2024 as patients reschedule bariatric procedures.
The approval makes Recor the first company to bring the treatment to the U.S. after getting an FDA panel nod in August.
Recor wins FDA approval for renal denervation system Read More »
The analysis adds to a growing body of research highlighting the burden of healthcare costs in the U.S., even for families with higher incomes.
Healthcare financial strain is ‘widespread’ in U.S., study finds Read More »
The agency claims intellectual property for emergency allergy shot EpiPen and asthma medication Advair was “improperly listed” in a Food and Drug Administration database.
FTC challenges patents held by nine big drugmakers, citing unfair competition Read More »
The move could further integrate the retail giant’s healthcare ambitions with its core ecommerce business.
Amazon discounts One Medical membership for Prime customers to $9 a month Read More »
The tech retailer notched similar partnerships to co-develop home care products with Geisinger and Atrium earlier this year.
Best Buy inks third health system product development deal, with Mass General Brigham Read More »
This week (our inaugural episode!) BioSpace’s Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma’s reported Q3 earnings. They also tackle what’s going on at Pfizer, ADCs, deals and more.
